Chemosensitivity prediction in esophageal squamous cell carcinoma: Novel marker genes and efficacy-prediction formulae using their expression data

International Journal of Oncology

Volumn 28, Issue 5, 2006, Pages 1153-1162

  Shimokuni, Tatsushi ^a,e   Tanimoto, Keiji ^a   Hiyama, Keiko ^a   Otani, Keiko ^a   Ohtaki, Megu ^a   Hihara, Jun ^a   Yoshida, Kazuhiro ^a   Noguchi, Tsuyoshi ^b   Kawahara, Katsunobu ^b   Natsugoe, Shoji ^c   Aikou, Takashi ^c   Okazaki, Yasushi ^d   Hayashizaki, Yoshihide ^d   Sato, Yuji ^e   Todo, Satoru ^e   Hiyama, Eiso ^a   Nishiyama, Masahiko ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b OITA UNIVERSITY   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

^d RIKEN YOKOHAMA INSTITUTE   (Japan)

^e HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Drug sensitivity; Esophageal cancer; Gene expression; Microarray; Personalized medicine

Indexed keywords

ANTINEOPLASTIC AGENT; RNA;

ARTICLE; CELL CULTURE; DISEASE FREE SURVIVAL; DNA MICROARRAY; DRUG EFFECT; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETICS; HUMAN; PREDICTION AND FORECASTING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELLS, CULTURED; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TREATMENT OUTCOME;

EID: 33646851428     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.5.1153     Document Type: Article

References (47)

1. Koshy M, Esiashvilli N, Landry JC, Thomas CR Jr and Matthews RH: Multiple management modalities in esophageal cancer: epidemiology, presentation and progression, work-up, and surgical approaches. Oncologist 9: 137-146, 2004.
2. Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, Koussis H, Zaninotto G, Bonavina L and Peracchia A: Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 91: 2165-2174, 2001.
3. Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, Takiyama W, Watanabe H, Isono K, Aoyama N, Makuuchi H, Tanaka O, Yamana H, Ikeuchi S, Kabuto T, Nagai K, Shimada Y, Kinjo Y and Fukuda H: Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study-JCOG9204. J Clin Oncol 21: 4592-4596, 2003.
4. Tak VM and Naunheim KS: Current status of multimodality therapy for esophageal carcinoma. J Surg Res 117: 22-29, 2004.
5. Adlard JW, Richman SD, Seymour MT and Quirke P: Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol 3: 75-82, 2002.
6. Evans WE and Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286: 487-491, 1999.
7. Iqbal S and Lenz HJ: Targeted therapy and pharmacogenomic programs. Cancer 97: 2076-2082, 2003.
8. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO and Weinstein JN: A gene expression database for the molecular pharmacology of cancer. Nat Genet 24: 236-244, 2000. (Pubitemid 30132190)
9. McLeod HL and Evans WE: Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 41: 101-121, 2001.
10. Staunton JE, Slonim DK, Coller HA, Tamayo P, Angelo MJ, Park J, Scherf U, Lee JK, Reinhold WO, Weinstein JN, Mesirov JP, Lander ES and Golub TR: Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 98: 10787-10792, 2001.
11. Tanaka T, Tanimoto K, Otani K, Satoh K, Ohtaki M, Yoshida K, Toge T, Yahata H, Tanaka S, Chayama K, Okazaki Y, Hayashizaki Y, Hiyama K and Nishiyama M: Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer 111: 617-626, 2004.
12. Morita T, Togo S, Kubota T, Kamimukai N, Nishizuka I, Kobayashi T, Ichikawa Y, Ishikawa T, Takahashi S, Matsuo K, Tomaru Y, Okazaki Y, Hayashizaki Y and Shimada H: Mechanism of postoperative liver failure after excessive hepatectomy investigated using a cDNA microarray. J Hepatobiliary Pancreat Surg 9: 352-359, 2002.
13. Hiyama K, Otani K, Ohtaki M, Satoh K, Kumazaki T, Takahashi T, Mitsui Y, Okazaki Y, Hayashizaki Y, Omatsu H, Noguchi T, Tanimoto K and Nishiyama M: Differentially expressed genes throughout the cellular immortalization processes are quite different between normal human fibroblasts and endothelial cells. Int J Oncol 27: 87-95, 2005.
14. Ohtaki M, Otani K, Satoh K, Kawamura T, Hiyama K and Nishiyama M: Model-based analysis of microarray data: exploration of differentially expressed genes between two cell types based on a two-dimensional mixed normal model. Jpn J Biometrics 26: 31-48, 2005.
15. Rousseeuw PJ: Least median of squares regression. J Am Statist Assoc 79: 871-880, 1984.
16. Chung YM, Park S, Park JK, Kim Y, Kang Y and Yoo YD: Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells. Cancer Lett 159: 95-101, 2000.
17. Cresteil T, Monsarrat B, Dubois J, Sonnier M, Alvinerie P and Gueritte F: Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship. Drug Metab Dispos 30: 438-445, 2002.
18. Davis JM, Navolanic PM, Weinstein-Oppenheimer CR, Steelman LS, Hu W, Konopleva M, Blagosklonny MV and McCubrey JA: Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin Cancer Res 9: 1161-1170, 2003.
19. Diasio RB and Johnson MR: Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res 5: 2672-2673, 1999.
20. Gorrini C, Donzelli M, Torriglia A, Supino R, Brison O, Bernardi R, Negri C, Denegri M, Counis MF, Ranzani GN and Scovassi AI: Effect of apoptogenic stimuli on colon carcinoma cell lines with a different c-myc expression level. Int J Mol Med 11: 737-742, 2003.
21. Goto S, Ihara Y, Urata Y, Izumi S, Abe K, Koji T and Kondo T: Doxorubicin-induced DNA intercalation and scavenging by nuclear glutathione S-transferase π. FASEB J 15: 2702-2714, 2001.
22. Goto S, Kamada K, Soh Y, Ihara Y and Kondo T: Significance of nuclear glutathione S-transferase π in resistance to anticancer drugs. Jpn J Cancer Res 93: 1047-1056, 2002.
23. Grassilli E, Ballabeni A, Maellaro E, Del Bello B and Helin K: Loss of MYC confers resistance to doxorubicin-induced apoptosis by preventing the activation of multiple serine protease- and caspase-mediated pathways. J Biol Chem 279: 21318-21326, 2004.
24. Hayes MC, Birch BR, Cooper AJ and Primrose JN: Cellular resistance to mitomycin C is associated with overexpression of MDR-1 in a urothelial cancer cell line (MGH-U1). BJU Int 87: 245-250, 2001.
25. Hidaka S, Yasutake T, Fukushima M, Yano H, Haseba M, Tsuji T, Sawai T, Yamaguchi H, Nakagoe T, Ayabe H and Tagawa Y: Chromosomal imbalances associated with acquired resistance to fluoropyrimidines in human colorectal cancer cells. Eur J Cancer 39: 975-980, 2003.
26. Iida T, Mori E, Mori K, Goto S, Urata Y, Oka M, Kohno S and Kondo T: Co-expression of gamma-glutamylcysteine synthetase sub-units in response to cisplatin and doxorubicin in human cancer cells. Int J Cancer 82: 405-411, 1999.
27. Knowlton K, Mancini M, Creason S, Morales C, Hockenbery D and Anderson BO: Bcl-2 slows in vitro breast cancer growth despite its antiapoptotic effect. J Surg Res 76: 22-26, 1998.
28. Maitra R, Halpin PA, Karlson KH, Page RL, Paik DY, Leavitt MO, Moyer BD, Stanton BA and Hamilton JW: Differential effects of mitomycin C and doxorubicin on P-glycoprotein expression. Biochem J 355: 617-624, 2001.
29. Nishiyama M, Suzuki K, Kumazaki T, Yamamoto W, Toge T, Okamura T and Kurisu K: Molecular targeting of mitomycin C chemotherapy. Int J Cancer 72: 649-656, 1997.
30. Noguchi T, Tanimoto K, Shimokuni T, Ukon K, Tsujimoto H, Fukushima M, Noguchi T, Kawahara K, Hiyama K and Nishiyama M: Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells. Clin Cancer Res 10: 7100-7107, 2004.
31. Okamoto R, Takano H, Okamura T, Park JS, Tanimoto K, Sekikawa T, Yamamoto W, Sparreboom A, Verweij J and Nishiyama M: O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives. Jpn J Cancer Res 93: 93-102, 2002.
32. Park SY, Lam W and Cheng YC: X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance. Cancer Res 62: 459-465, 2002.
33. Plo I, Liao ZY, Barcelo JM, Kohlhagen G, Caldecott KW, Weinfeld M and Pommier Y: Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions. DNA Repair 2: 1087-1100, 2003.
34. Pourquier P, Waltman JL, Urasaki Y, Loktionova NA, Pegg AE, Nitiss JL and Pommier Y: Topoisomerase I-mediated cytotoxicity of N-methyl-N′-nitro-N- nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine. Cancer Res 61: 53-58, 2001.
35. Rasheed ZA and Rubin EH: Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene 22: 7296-7304, 2003.
36. Tani M, Goto S, Kamada K, Mori K, Urata Y, Ihara Y, Kijima H, Ueyama Y, Shibata S and Kondo T: Hammerhead ribozyme against gamma-glutamylcysteine synthetase attenuates resistance to ionizing radiation and cisplatin in human T98G glioblastoma cells. Jpn J Cancer Res 93: 716-722, 2002.
37. Thomas CJ, Rahier NJ and Hecht SM: Camptothecin: current perspectives. Bioorg Med Chem 12: 1585-1604, 2004.
38. Clarke PA, te Poele R, Wooster R and Workman P: Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential. Biochem Pharmacol 62: 1311-1336, 2001.
39. Watters JW and McLeod HL: Cancer pharmacogenomics: current and future applications. Biochim Biophys Acta 1603: 99-111, 2003.
40. Kihara C, Tsunoda T, Tanaka T, Yamana H, Furukawa Y, Ono K, Kitahara O, Zembutsu H, Yanagawa R, Hirata K, Takagi T and Nakamura Y: Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res 61: 6474-6479, 2001.
41. Akyerli CB, Beksac M, Holko M, Frevel M, Dalva K, Ozbek U, Soydan E, Ozcan M, Ozet G, Ilhan O, Gurman G, Akan H, Williams BR and Ozcelik T: Expression of IFITM1 in chronic myeloid leukemia patients. Leuk Res 29: 283-286, 2005.
42. Burd CG, Strochlic TI and Gangi Setty SR: Arf-like GTPases: not so Arf-like after all. Trends Cell Biol 14: 687-694, 2004.
43. Grumet M: Nr-CAM: a cell adhesion molecule with ligand and receptor functions. Cell Tissue Res 290: 423-428, 1997.
44. Ichikawa S, Sakiyama H, Suzuki G, Hidari KI and Hirabayashi Y: Expression cloning of a cDNA for human ceramide glucosyltransferase that catalyzes the first glycosylation step of glycosphingolipid synthesis. Proc Natl Acad Sci USA 93: 4638-4643, 1996.
45. Paschen W: Endoplasmic reticulum: a primary target in various acute disorders and degenerative diseases of the brain. Cell Calcium 34: 365-383, 2003.
46. Sato T, Furukawa K, Bakker H, van den Eijnden DH and van Die I: Molecular cloning of a human cDNA encoding beta-1,4-galactosyltransferase with 37% identity to mammalian UDP-Gal:GlcNAc beta-1,4-galactosyltransferase. Proc Natl Acad Sci USA 95: 472-477, 1998.
47. Yabe D, Taniwaki M, Nakamura T, Kanazawa N, Tashiro K and Honjo T: Human calumenin gene (CALU): cDNA isolation and chromosomal mapping to 7q32. Genomics 49: 331-333, 1998.